Clinical evaluation method for predicting curative effect of gastric cancer chemotherapy combined with immunotherapy

Through clinical evaluation models of skeletal muscle radioactivity attenuation value, neutrophil count ratio and weight loss ratio, the efficacy of gastric cancer chemotherapy combined with immunotherapy was predicted, which solved the problem of difficulty in predicting efficacy in the existing technology and improved the prediction Accuracy and therapeutic effect.

CN118942718APending Publication Date: 2024-11-12RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410920250.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-10
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively predict the efficacy of gastric cancer chemotherapy combined with immunotherapy, resulting in an increase in the risk of adverse reactions and low efficacy. The proportion of positive current markers is low, and the clinical characteristics of patients are not fully considered.

Method used

The radioactivity attenuation value of skeletal muscle, the ratio of neutrophil count to lymphocyte count and the ratio of weight loss were used as parameters of the clinical evaluation model. By establishing thresholds and grouping, the efficacy of gastric cancer chemotherapy combined with immunotherapy was predicted.

Benefits of technology

It improves the accuracy of predicting efficacy of chemotherapy combined with immunotherapy, reduces the risk of adverse reactions, helps identify potentially effective patient populations, and provides important information to guide the selection of treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118942718A_ABST
    Figure CN118942718A_ABST
Patent Text Reader

Abstract

The invention discloses a clinical evaluation method for predicting the curative effect of gastric cancer chemotherapy combined with immunotherapy, and the method comprises the following steps: S1, screening patients, and obtaining the characteristic data of the patients, comprise a skeletal muscle radioactivity attenuation value of a patient based on CT imaging body composition analysis, a ratio of neutrophil count to lymphocyte count of a blood routine result and a weight loss proportion; s2, establishing a clinical evaluation model by using the characteristic data of the patient, comparing a skeletal muscle radioactivity attenuation value, a ratio of neutrophil count to lymphocyte count and a weight loss proportion of the patient with each parameter threshold value in the clinical evaluation model, and grouping the skeletal muscle radioactivity attenuation value, the ratio of neutrophil count to lymphocyte count and the weight loss proportion; and S3, according to the grouping condition of the patient in the clinical evaluation model, obtaining a prediction result of the chemotherapy and immunotherapy combined curative effect of the patient. The method can be used as an effective supplement of an existing stomach cancer immunotherapy curative effect prediction system, and the immunotherapy curative effect prediction accuracy is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gastric cancer treatment, and in particular to a clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer. Background Art

[0002] At present, drug therapy is the main treatment strategy for patients with locally advanced inoperable or metastatic gastric cancer. The immune checkpoint inhibitor PD-1 monoclonal antibody combined with chemotherapy has become one of the standard first-line treatment strategies for such patients. However, not all patients can benefit from this treatment, and ineffective patients may be exposed to immune-related adverse reactions, increasing the risk of treatment-related toxicity. Exploring and clarifying efficacy-related markers is an effective strategy to improve the efficacy of chemotherapy combined with immunotherapy for gastric cancer. Currently known predictive markers related to the efficacy of gastric cancer immunotherapy include PD-1 expression, microsatellite instability, and tumor mutation load, but the positive rate of such markers in advanced gastric cancer is relatively low, and they are all tumor-related molecular markers, requiring specific detection methods. Patient clinical characteristics are also an important factor affecting the efficacy of immunotherapy, but have not yet been included in the prediction system for the efficacy of gastric cancer immunotherapy. Summary of the invention

[0003] The purpose of the present invention is to provide a clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer, so as to solve the problems raised in the above background technology.

[0004] To achieve the above-mentioned purpose of the invention, the present invention provides a clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer, comprising the following steps:

[0005] Step S1, screening patients and obtaining patient characteristic data, including the skeletal muscle radioactive attenuation value based on CT imaging body composition analysis, the neutrophil count to lymphocyte count ratio of blood routine results, and the weight loss ratio;

[0006] Step S2, using the patient characteristic data to establish a clinical evaluation model, comparing the patient's skeletal muscle radioactive attenuation value, neutrophil count to lymphocyte count ratio, and weight loss ratio with the threshold values ​​of each parameter in the clinical evaluation model, and grouping;

[0007] Step S3, obtaining the predicted results of the chemotherapy combined with immunotherapy efficacy of the patients according to the grouping of the patients in the clinical evaluation model.

[0008] Furthermore, before step S2, it is necessary to:

[0009] The correlation analysis was performed between the patients' skeletal muscle radioactive attenuation values, neutrophil count to lymphocyte count ratio, weight loss ratio and the patients' efficacy data to obtain the cutoff values ​​and grouping of each parameter in the clinical evaluation model;

[0010] Furthermore, the skeletal muscle radioactive attenuation value refers to the average radioactive attenuation value of the skeletal muscle marked at the third lumbar plane in the CT examination image of the patient before treatment;

[0011] The neutrophil count to lymphocyte count ratio refers to the ratio of the neutrophil count to the lymphocyte count in the patient's routine blood examination before treatment;

[0012] The weight loss ratio refers to the weight loss ratio of the patient within 6 months before treatment;

[0013] Furthermore, the establishment of the clinical evaluation model also includes:

[0014] Obtain preset thresholds for skeletal muscle radioactive attenuation values, neutrophil count to lymphocyte count ratio, and weight loss ratio;

[0015] The clinical evaluation model was constructed based on the above three parameter thresholds and grouped.

[0016] Furthermore, the threshold is set as follows:

[0017] For skeletal muscle radioactive attenuation values, body mass index < 24 kg / m 2 For patients with

[0018] ≥24kg / m 2 For patients with

[0019] For the neutrophil-to-lymphocyte ratio, the threshold was 2.65;

[0020] The percentage of body weight lost, with a threshold of 5%;

[0021] Furthermore, the step S2 includes the following steps:

[0022] Step S201, comparing the skeletal muscle radioactive attenuation value, the neutrophil count to lymphocyte count ratio, and the weight loss ratio with a preset threshold value of a clinical model;

[0023] Step S202, according to the comparison results, the patients are classified into three clinical groups, namely, "good efficacy", "moderate efficacy" and "poor efficacy", and the corresponding chemotherapy combined with immunotherapy efficacy prediction results are obtained.

[0024] Furthermore, the three clinical groups are based on:

[0025] The “good efficacy” group consisted of skeletal muscle radioactive attenuation values ​​greater than the threshold, neutrophil-to-lymphocyte ratio <2.65, and body weight loss <5%;

[0026] The “moderate efficacy” group was defined as the skeletal muscle radioactive attenuation value greater than the threshold, the neutrophil to lymphocyte ratio

[0027] ≥2.65, and / or weight loss ≥5%;

[0028] The “poor efficacy” group was defined as the skeletal muscle radioactive attenuation value being less than the threshold.

[0029] Furthermore, the disease condition of the gastric cancer patient is locally advanced or advanced metastatic gastric cancer that is first diagnosed and has not been treated with drugs, and the patient's general condition is suitable for chemotherapy combined with immunotherapy as a first-line treatment option.

[0030] Compared with the prior art, the present system and method have the following advantages:

[0031] The clinical evaluation method proposed in the present invention uses clinically easily accessible parameters, including skeletal muscle radioactive decay, neutrophil-to-lymphocyte ratio, and weight loss. This clinical evaluation model provides important information for guiding the selection of clinical treatment plans, and can serve as an effective supplement to the existing gastric cancer immunotherapy efficacy prediction system, which helps to enrich the potential effective population, reduce the risk of treatment-related adverse reactions, and improve the accuracy of immunotherapy efficacy prediction. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a flow chart of a clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer.

[0033] Figure 2 This is a diagram showing the distribution of the efficacy of chemotherapy combined with immunotherapy for gastric cancer predicted by the efficacy evaluation model in Example 1 of the present invention. DETAILED DESCRIPTION

[0034] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] like Figure 1 The flowchart of the method of the present invention is shown. The embodiment of the present invention provides a method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer. In the present invention, the data comes from gastric cancer patients, and clinically easy-to-obtain parameters are included, including three parameters of skeletal muscle radiation attenuation (SMRA), neutrophil to lymphocyte ratio (NLR) and weight loss in gastric cancer patients.

[0036] The specific steps include the following three steps.

[0037] Step S1, screening patients and obtaining patient characteristic data, including the skeletal muscle radioactive attenuation value of the patient based on CT imaging body composition analysis, the neutrophil count to lymphocyte count ratio of blood routine results, and the weight loss ratio.

[0038] First, we obtained the treatment data of 202 gastric cancer patients, screened and recorded the treatment data of 202 gastric cancer patients in our center, including 120 patients who received chemotherapy combined with immunotherapy and 82 patients who received chemotherapy only. Among them, the patients had to meet the following inclusion criteria:

[0039] 1) Complete medical history information;

[0040] 2) receiving chemotherapy combined with immunotherapy, or chemotherapy alone;

[0041] 3) receiving radical gastrectomy or palliative gastric tumor resection after treatment;

[0042] 4) Complete blood routine data;

[0043] 5) Complete CT imaging data before treatment.

[0044] Based on the clinical data and body composition data characteristics of patients receiving chemotherapy combined with immunotherapy and patients receiving chemotherapy only, as well as the corresponding therapeutic effects, SPSS software was used for correlation analysis and feature screening. The screened features included: skeletal muscle radiation failure, the ratio of neutrophils to lymphocytes, and the proportion of weight loss.

[0045] The medical history of patients before treatment was sorted out, and basic information such as age, gender, height, weight, weight loss, clinical stage, pathological stage, progression-free survival time, and survival time were collected. The results of routine blood tests before treatment were collected, including neutrophil count and lymphocyte count. The ratio of neutrophils to lymphocytes was calculated. The weight loss of patients before treatment was recorded, and the weight loss ratio (percentage %) was calculated.

[0046] The enhanced CT images of the patients during the baseline evaluation before treatment were sorted out to obtain the images at the third lumbar level (venous phase), and the image format was DICOM. The skeletal muscle part in the image was marked using sliceOmatic software, and the skeletal muscle radioactive attenuation value was calculated by the software. The unit was Hounsfield Unit (HU).

[0047] The therapeutic efficacy of the patients was evaluated by tumor regression grade (TRG) of surgical resection specimens: no residual tumor cells (including lymph nodes) was called complete remission (TRG=0); only single or small foci of cancer cells remained, which was called near-complete remission (TRG=1); tumor residues but less than fibrotic stroma were called partial remission (TGR=2); extensive tumor residues with no or little tumor cell necrosis were called no remission (TRG=3).

[0048] Immunotherapy is an immunotherapy using PD-1 monoclonal antibodies. The PD-1 monoclonal antibodies of the present invention include but are not limited to Pembrolizumab, Nivolumab, Sintilimab, and Carrelizumab.

[0049] Step S2, using the patient characteristic data to establish a clinical evaluation model, comparing the patient's skeletal muscle radioactive attenuation value, neutrophil count to lymphocyte count ratio, and weight loss ratio with the cutoff value of each parameter in the clinical evaluation model, and grouping.

[0050] Before step S2, it is necessary to conduct a correlation analysis between the patient's skeletal muscle radioactive attenuation value, neutrophil count to lymphocyte count ratio, weight loss ratio and the patient's efficacy data to obtain the cutoff value and grouping of each parameter in the clinical evaluation model.

[0051] Thresholds were set for the above three parameters, and the threshold for skeletal muscle radioactive attenuation was set as: body mass index < 24 kg / m 2 Patients with SMRA < 41HU and body mass index ≥ 24 kg / m 2 For patients with SMRA < 33HU; the threshold for the neutrophil-to-lymphocyte ratio is set to: < 2.65; the threshold for weight loss ratio is: ≥ 5%;

[0052] According to the above cutoff values, a clinical evaluation model was constructed and divided into three groups:

[0053] Group 1 (“good efficacy”): high SMRA with NLR <2.65 and weight loss <5%;

[0054] Group 2 (“moderate efficacy”): high SMRA with NLR ≥ 2.65 and / or weight loss ≥ 5%;

[0055] Group 3 ("poor efficacy"): low SMRA.

[0056] When receiving chemotherapy combined with immunotherapy, patients in Group 1 were shown to achieve a higher effective rate, followed by patients in Group 2, and patients in Group 3 were less likely to benefit from the treatment.

[0057] like Figure 2The figure shows the distribution of the efficacy of patients in chemotherapy combined with immunotherapy for gastric cancer predicted by this method, where IO cohort is the chemotherapy combined with immunotherapy group, and CTx cohort is the chemotherapy alone group. It can be seen from the figure that in IO cohort, the pathological remission of the three groups of patients after receiving chemotherapy combined with immunotherapy has significant differences. Among them, the proportion of TRG0 / 1 level in patients evaluated as "good efficacy" is 67.5%; the proportion of TGR0 / 1 level in patients with "moderate efficacy" is 41.3%; the proportion of TRG0 / 1 level in patients with "poor efficacy" is 11.8%, and the efficacy among the three groups shows a decreasing trend. In CTx cohort, the pathological remission between the three groups of patients after receiving chemotherapy alone did not show a similar phenomenon to that of IO cohort. Among them, the proportion of TRG0 / 1 level in patients evaluated as "good efficacy" is 34.8%; the proportion of TGR0 / 1 level in patients with "moderate efficacy" is 36.2%; the proportion of TRG0 / 1 level in patients with "poor efficacy" is 16.7%. The results showed that the constructed clinical evaluation model can effectively indicate the efficacy of chemotherapy combined with immunotherapy in patients with gastric cancer, rather than chemotherapy alone.

[0058] Step S3, obtaining the predicted results of the chemotherapy combined with immunotherapy efficacy of the patients according to the grouping of the patients in the clinical evaluation model.

[0059] For a gastric cancer patient who received chemotherapy combined with PD-1 monoclonal antibody therapy, the patient's clinical parameter evaluation before treatment showed that the skeletal muscle radioactive attenuation value was 57.6HU, the neutrophil-to-lymphocyte ratio was 2.63, and the weight loss was 0%, which met the criteria of group 1 patients in the clinical evaluation model. After treatment, the tumor regression grade (TRG) in the surgical pathological specimen of the primary gastric cancer lesion was 0, and the patient was evaluated as pathological complete remission, indicating benefit from the treatment regimen.

[0060] For another gastric cancer patient who received chemotherapy combined with PD-1 monoclonal antibody treatment, the patient's previous clinical parameter evaluation showed that the skeletal muscle radioactive attenuation value was 39.26HU, the neutrophil-to-lymphocyte ratio was 4.96, and the weight loss was 11.2%, which met the criteria of group 3 patients in the clinical evaluation model. After treatment, the tumor regression grade (TRG) of the surgical pathological specimen of the primary gastric cancer lesion was grade 3, and the patient was evaluated as having no pathological remission, indicating that he did not benefit from the treatment regimen.

[0061] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer, characterized in that: The following steps are involved: Step S1, screening patients and obtaining patient characteristic data, including the skeletal muscle radioactive attenuation value based on CT imaging body composition analysis, the neutrophil count to lymphocyte count ratio of blood routine results, and the weight loss ratio; Step S2, using the patient characteristic data to establish a clinical evaluation model, comparing the patient's skeletal muscle radioactive attenuation value, neutrophil count to lymphocyte count ratio, and weight loss ratio with the threshold values ​​of each parameter in the clinical evaluation model, and grouping them; Step S3, obtaining the predicted results of the chemotherapy combined with immunotherapy efficacy of the patients according to the grouping of the patients in the clinical evaluation model.

2. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer according to claim 1, characterized in that: Before step S2: The correlation analysis was performed between the patients' skeletal muscle radioactive attenuation values, neutrophil count to lymphocyte count ratio, weight loss ratio and the patients' efficacy data to obtain the cutoff values ​​and grouping of each parameter in the clinical evaluation model.

3. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer according to claim 1, characterized in that: The skeletal muscle radioactive attenuation value refers to the average radioactive attenuation value of the skeletal muscle marked at the third lumbar vertebra plane in the CT examination image of the patient before treatment; The neutrophil count to lymphocyte count ratio refers to the ratio of the neutrophil count to the lymphocyte count in the patient's routine blood examination before treatment; The weight loss ratio refers to the weight loss ratio of the patient within 6 months before treatment.

4. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer according to claim 1, characterized in that: The establishment of the clinical evaluation model also includes: Obtain preset thresholds for skeletal muscle radioactive attenuation values, neutrophil count to lymphocyte count ratio, and weight loss ratio; The clinical evaluation model was constructed based on the above three parameter thresholds and grouped.

5. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer according to claim 4, characterized in that: The thresholds are set as follows: For skeletal muscle radioactive attenuation values, body mass index < 24 kg / m 2 For patients with ≥24kg / m 2 For patients with For the neutrophil-to-lymphocyte ratio, the threshold was 2.65; The percentage of weight loss was 5%.

6. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer according to claim 4 or 5, characterized in that: The step S2 comprises the following steps: Step S201, comparing the skeletal muscle radioactive attenuation value, the neutrophil count to lymphocyte count ratio, and the weight loss ratio with a preset threshold value of a clinical model; Step S202, according to the comparison results, the patients are classified into three clinical groups, "good efficacy", "moderate efficacy" and "poor efficacy", and the corresponding chemotherapy combined with immunotherapy efficacy prediction results are obtained.

7. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer according to claim 6, characterized in that: The three clinical groups are based on: The "good efficacy" group was defined as skeletal muscle radioactive attenuation values ​​greater than the threshold, neutrophil-to-lymphocyte ratio <2.65, and body weight loss <5%; The "moderate efficacy" group was defined as the skeletal muscle radioactive attenuation value greater than the threshold, the neutrophil to lymphocyte ratio ≥2.65, and / or weight loss ≥5%; The "poor efficacy" group was defined as the skeletal muscle radioactive attenuation value being less than the threshold.

8. A clinical evaluation method for predicting the efficacy of chemotherapy combined with immunotherapy for gastric cancer according to claim 1, characterized in that: The disease condition of the gastric cancer patient is locally advanced or advanced metastatic gastric cancer that has been diagnosed for the first time and has not been treated with drugs. The patient's general condition is suitable for chemotherapy combined with immunotherapy as a first-line treatment option.